Pharmacokinetics of 2',3'-dideoxycytidine in patients with AIDS and related disorders.

PubWeight™: 1.51‹?› | Rank: Top 4%

🔗 View Article (PMID 2852679)

Published in J Clin Pharmacol on September 01, 1988

Authors

R W Klecker1, J M Collins, R C Yarchoan, R Thomas, N McAtee, S Broder, C E Myers

Author Affiliations

1: Clinical Oncology Program, National Cancer Institute, Bethesda, Maryland.

Articles citing this

Effects of drugs on 2',3'-dideoxy-2',3'-didehydrothymidine phosphorylation in vitro. Antimicrob Agents Chemother (1997) 1.66

Safety and pharmacokinetics of abacavir (1592U89) following oral administration of escalating single doses in human immunodeficiency virus type 1-infected adults. Antimicrob Agents Chemother (1999) 1.39

Oral, subcutaneous, and intramuscular bioavailabilities of the antiviral nucleotide analog 9-(2-phosphonylmethoxyethyl) adenine in cynomolgus monkeys. Antimicrob Agents Chemother (1994) 1.18

Pharmacokinetics of saquinavir, zidovudine, and zalcitabine in combination therapy. Antimicrob Agents Chemother (1997) 1.01

Ultrastructural changes associated with reduced mitochondrial DNA and impaired mitochondrial function in the presence of 2'3'-dideoxycytidine. Antimicrob Agents Chemother (1992) 0.90

Absolute bioavailability and disposition of (-) and (+) 2'-deoxy- 3'-oxa-4'-thiocytidine (dOTC) following single intravenous and oral doses of racemic dOTC in humans. Antimicrob Agents Chemother (2000) 0.84

Pharmacokinetics and distribution over the blood-brain barrier of zalcitabine (2',3'-dideoxycytidine) and BEA005 (2', 3'-dideoxy-3'-hydroxymethylcytidine) in rats, studied by microdialysis. Antimicrob Agents Chemother (1998) 0.82

Effect of food on the bioavailability of stavudine in subjects with human immunodeficiency virus infection. Antimicrob Agents Chemother (1998) 0.81

In vitro potency of inhibition by antiviral drugs of hematopoietic progenitor colony formation correlates with exposure at hemotoxic levels in human immunodeficiency virus-positive humans. Antimicrob Agents Chemother (1996) 0.79

Zalcitabine population pharmacokinetics: application of radioimmunoassay. Antimicrob Agents Chemother (1998) 0.78

Application of a radioimmunoassay for determination of levels of zalcitabine (ddC) in human plasma, urine, and cerebrospinal fluid. Antimicrob Agents Chemother (1994) 0.78

In vitro activities of nucleoside analog antiviral agents against salmonellae. Antimicrob Agents Chemother (1993) 0.76

Pharmacokinetics of 2-fluorodideoxycytidine (2FddC) in patients infected with human immunodeficiency virus. Br J Clin Pharmacol (1993) 0.75

Articles by these authors

The sequence of the human genome. Science (2001) 101.55

Changing provider behavior: an overview of systematic reviews of interventions. Med Care (2001) 17.89

A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells. J Immunol (1981) 10.92

3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci U S A (1985) 10.71

Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci U S A (1986) 8.48

Role of suppressor T cells in pathogenesis of common variable hypogammaglobulinaemia. Lancet (1974) 8.13

Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci U S A (1994) 6.74

Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides. Proc Natl Acad Sci U S A (1986) 6.63

An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord (1997) 5.94

Design and use of questionnaires: a review of best practice applicable to surveys of health service staff and patients. Health Technol Assess (2001) 5.84

Phosphorothioate analogs of oligodeoxynucleotides: inhibitors of replication and cytopathic effects of human immunodeficiency virus. Proc Natl Acad Sci U S A (1987) 5.17

Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci U S A (1988) 4.77

A simplified acute physiology score for ICU patients. Crit Care Med (1984) 4.55

Boolean formalization of genetic control circuits. J Theor Biol (1973) 4.54

Molecular targets for AIDS therapy. Science (1990) 4.28

Infectious mutants of HTLV-III with changes in the 3' region and markedly reduced cytopathic effects. Science (1986) 4.17

Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. JAMA (2000) 3.99

Impaired synthesis of polyclonal (non-paraprotein) immunoglobulins by circulating lymphocytes from patients with multiple myeloma Role of suppressor cells. N Engl J Med (1975) 3.81

A pathogenic retrovirus (HTLV-III) linked to AIDS. N Engl J Med (1984) 3.41

Genetics and physiology of defective lysogeny in K12 (lambda): studies of early mutants. Virology (1966) 3.39

Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT). Lancet (1988) 3.37

Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science (1977) 3.11

Dextran sulfate suppression of viruses in the HIV family: inhibition of virion binding to CD4+ cells. Science (1988) 3.01

Strategies for antiviral therapy in AIDS. Nature (1987) 2.95

The cardio-toxicity of isoprenaline during hypoxia. Br J Pharmacol (1969) 2.94

Plasma and cerebrospinal fluid pharmacokinetics of 3'-azido-3'-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases. Clin Pharmacol Ther (1987) 2.92

Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells. J Biol Chem (1986) 2.88

High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol (1998) 2.77

In vivo activity against HIV and favorable toxicity profile of 2',3'-dideoxyinosine. Science (1989) 2.70

Suramin protection of T cells in vitro against infectivity and cytopathic effect of HTLV-III. Science (1984) 2.70

A cloud adult: the Staphylococcus aureus-virus interaction revisited. Ann Intern Med (1996) 2.66

Corneal thickness in ocular hypertension, primary open-angle glaucoma, and normal tension glaucoma. Arch Ophthalmol (1999) 2.65

Regulation of viral expression of human immunodeficiency virus in vitro by an antisense phosphorothioate oligodeoxynucleotide against rev (art/trs) in chronically infected cells. Proc Natl Acad Sci U S A (1989) 2.62

Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev (2006) 2.59

Thyroxine should be tried in clinically hypothyroid but biochemically euthyroid patients. BMJ (1997) 2.58

Prevalence of primary glaucoma in an urban south Indian population. Indian J Ophthalmol (1998) 2.58

Characterization of monoclonal antibodies and polyclonal immune sera directed against human cytomegalovirus virion proteins. Virology (1984) 2.48

Hydrogen-poor superluminous stellar explosions. Nature (2011) 2.48

Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep (1978) 2.42

CD4 count and the risk for death in patients infected with HIV receiving antiretroviral therapy. Ann Intern Med (1991) 2.35

The Sézary syndrome: a malignant proliferation of helper T cells. J Clin Invest (1976) 2.32

An open randomised trial of second-line endocrine therapy in advanced breast cancer. comparison of the aromatase inhibitors letrozole and anastrozole. Eur J Cancer (2003) 2.31

A comparison of batch effect removal methods for enhancement of prediction performance using MAQC-II microarray gene expression data. Pharmacogenomics J (2010) 2.30

Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. J Clin Invest (1993) 2.27

Clinical pharmacology of 3'-azido-2',3'-dideoxythymidine (zidovudine) and related dideoxynucleosides. N Engl J Med (1989) 2.17

Fraud in breast-cancer trials. N Engl J Med (1994) 2.16

In vivo detection of multidrug-resistant (MDR1) phenotype by technetium-99m sestamibi scan in untreated breast cancer patients. Eur J Nucl Med (1997) 2.15

Procalcitonin: a valuable indicator of infection in a medical ICU? Intensive Care Med (2000) 2.12

NIH conference. T-cell lymphoproliferative syndrome associated with human T-cell leukemia/lymphoma virus. Ann Intern Med (1984) 2.10

Initial studies on the cellular pharmacology of 2',3'-dideoxyinosine, an inhibitor of HIV infectivity. Biochem Pharmacol (1987) 2.10

Reduced soluble receptor for advanced glycation end-products in COPD. Eur Respir J (2010) 2.09

A prospective trial of lansoprazole triple therapy for pediatric Helicobacter pylori infection. J Pediatr Gastroenterol Nutr (2000) 2.09

Re: CT "invisible" lesion of the major salivary glands-a diagnostic pitfall of contrast-enhanced CT. Clin Radiol (2009) 2.08

Maternal smoking is associated with impaired neonatal toll-like-receptor-mediated immune responses. Eur Respir J (2006) 2.03

Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin. J Clin Invest (1980) 2.03

Influence of Dead Bacteria on Microscopic Counts of Pasteurized Milk. Am J Public Health Nations Health (1937) 2.02

Long-term toxicity/activity profile of 2',3'-dideoxyinosine in AIDS or AIDS-related complex. Lancet (1990) 2.02

The anthracycline antineoplastic drugs. N Engl J Med (1981) 2.02

Cortico-striatal contributions to feedback-based learning: converging data from neuroimaging and neuropsychology. Brain (2004) 2.00

Suppressor cells in the regulation of the immune response. Prog Clin Immunol (1977) 1.99

Replication of human immunodeficiency virus in monocytes. Granulocyte/macrophage colony-stimulating factor (GM-CSF) potentiates viral production yet enhances the antiviral effect mediated by 3'-azido-2'3'-dideoxythymidine (AZT) and other dideoxynucleoside congeners of thymidine. J Exp Med (1989) 1.99

Cell growth and lambda phage development controlled by the same essential Escherichia coli gene, ftsH/hflB. Proc Natl Acad Sci U S A (1993) 1.97

Long-term inhibition of human T-lymphotropic virus type III/lymphadenopathy-associated virus (human immunodeficiency virus) DNA synthesis and RNA expression in T cells protected by 2',3'-dideoxynucleosides in vitro. Proc Natl Acad Sci U S A (1987) 1.96

The socio-economic impact of telehealth: a systematic review. J Telemed Telecare (2003) 1.93

Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: an in vitro comparative study. Proc Natl Acad Sci U S A (1993) 1.92

Incidence of and risk factors for hallucinations and delusions in patients with probable AD. Neurology (2000) 1.91

Projections of the incidence of non-Hodgkin's lymphoma related to acquired immunodeficiency syndrome. J Natl Cancer Inst (1991) 1.91

Interventions to improve outpatient referrals from primary care to secondary care. Cochrane Database Syst Rev (2005) 1.88

Chromosome-specific single-locus FISH probes allow anchorage of an 1800-marker integrated radiation-hybrid/linkage map of the domestic dog genome to all chromosomes. Genome Res (2001) 1.88

Development of antiretroviral therapy for the acquired immunodeficiency syndrome and related disorders. A progress report. N Engl J Med (1987) 1.88

Panic disorder in the primary care setting: comorbidity, disability, service utilization, and treatment. J Clin Psychiatry (1999) 1.88

Pharmacokinetics of 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine in patients with severe human immunodeficiency virus infection. Clin Pharmacol Ther (1990) 1.87

Expression of anionic glutathione-S-transferase and P-glycoprotein genes in human tissues and tumors. Cancer Res (1989) 1.86

Mapping and functional analysis of y and CII mutants. Mutat Res (1969) 1.86

Isolation of the human anionic glutathione S-transferase cDNA and the relation of its gene expression to estrogen-receptor content in primary breast cancer. Proc Natl Acad Sci U S A (1988) 1.86

Polyclonal B-cell activators in the study of the regulation of immunoglobulin synthesis in the human system. Adv Immunol (1982) 1.85

Studies on the mechanism of human immunodeficiency virus reverse transcriptase. Steady-state kinetics, processivity, and polynucleotide inhibition. J Biol Chem (1988) 1.82

Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res (1996) 1.82

Pharmacologic rationale for regional drug delivery. J Clin Oncol (1984) 1.82

Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis. Brain (2003) 1.82

Constraints on CD4 recovery postchemotherapy in adults: thymic insufficiency and apoptotic decline of expanded peripheral CD4 cells. Blood (1997) 1.81

The role of diet and physical activity in breast, colorectal, and prostate cancer survivorship: a review of the literature. Br J Cancer (2011) 1.80

Fc-receptors on human T lymphocytes. I. Transition of Tgamma to Tmu cells. J Immunol (1978) 1.79

Potential roles for preclinical pharmacology in phase I clinical trials. Cancer Treat Rep (1986) 1.79

Cardiomyopathy: a systematic review of disease-causing mutations in myosin heavy chain 7 and their phenotypic manifestations. Cardiology (2009) 1.79

Ter, a function which generates the ends of the mature lambda chromosome. Nature (1969) 1.78

Disorders of suppressor immunoregulatory cells in the pathogenesis of immunodeficiency and autoimmunity. Ann Intern Med (1978) 1.78

Metabolism of diethylhexyl phthalate by rats. Isolation and characterization of the urinary metabolites. J Chromatogr (1973) 1.78

Characterization of human p53 antigens employing primate specific monoclonal antibodies. Virology (1983) 1.78

Incidence and management of posteriorly dislocated nuclear fragments following phacoemulsification. Indian J Ophthalmol (1999) 1.77

Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res (1994) 1.75

Intraosseous infusion. Br J Hosp Med (1994) 1.75

Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells. Proc Natl Acad Sci U S A (1998) 1.74

Functional properties of antigen-specific T cells infected by human T-cell leukemia-lymphoma virus (HTLV-I). Science (1984) 1.74

Ischemic colitis during treatment with alosetron. Gastroenterology (2001) 1.74